Clinical Trials at the PEI Cancer Treatment Centre

Below are the Clinical Trials that are currently being offered at the PEI Cancer Treatment Centre:

Gastrointestinal

Trial Name:  GA 3 - A Randomized Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)

Status:  Open for Recruitment
 

Trial Name: CRC.7 – A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer in Patient Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)

Status:  Open for Recruitment
 

Trial Name:  CRC3 - A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

Status:  Closed to Recruitment - Patients on Follow-up
 

Trial Name: CRC 6 -A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer

Status:  Closed to Recruitment - Patients on Follow-up

Breast

Trial Name:  MAC 21 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: THE ABC TRIAL

Status: Open for Recruitment
 

Trial Name:  MAC 13 -Adjuvant, Lapatinib and/or Trastuzumab Treatment Optimisation Study A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer

Status:  Closed to Recruitment - Patients on Follow-up

Trial Name:  MAC 15 - A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer

Status:  Closed to Recruitment - Patients on Follow-up

Trial Name:  MA 32 -A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer

Status:  Closed to Recruitment - Patients on Follow-up

Lung

Trial Name:  BR.31 – A Phase III Prospective Double-Blind Placebo-Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer

Status:  Open for Recruitment

Trial Name:  BR 34 - A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Open for Recruitment